Koo,

Various publications and posters available documenting the pre-clinical and clinical (Phase 2 post hoc) effects of apabetalone on eGFR, alkaline phosphatase and vascular calcification. Until we see the detailed BETonMACE Phase 3 data for the CKD subgroup, then yes the post-hoc Phase 2 data you describe is kind of the best clinical data to rely on. This Kidney and Blood Pressure Research paper is more thorough than the abstract you posted.

https://www.resverlogix.com/upload/media_element/attachments/41/Kidney%20&%20Blood%20Pressure%20Research.pdf

https://www.resverlogix.com/science-and-programs/publications